Personal Cfo Solutions, LLC Argenx Se Transaction History

Personal Cfo Solutions, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 22, 2021	SELL	$257.11 - $319.92 $469,482 - $584,173	-1,826 Closed	0 $0
Q1 2021 Apr 21, 2021	BUY	$268.3 - $380.31 $19,585 - $27,762	73 Added 4.16%	1,826 $503,000
Q4 2020 Feb 09, 2021	BUY	$248.13 - $308.36 $24,564 - $30,527	99 Added 5.99%	1,753 $515,000
Q3 2020 Nov 02, 2020	BUY	$215.51 - $272.51 $39,869 - $50,414	185 Added 12.59%	1,654 $0
Q2 2020 Aug 03, 2020	BUY	$127.44 - $232.72 $187,209 - $341,865	1,469 New	1,469 $331,000
Q1 2020 Apr 30, 2020	SELL	$108.83 - $165.23 $167,162 - $253,793	-1,536 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$106.59 - $164.21 $163,722 - $252,226	1,536 New	1,536 $247,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Personal Cfo Solutions, LLC, based on Form 13F filings with the SEC.

Stay updated on Personal Cfo Solutions, LLC with notifications on news.